Abstract:This bioequivalence study was conducted to evaluate two oral formulations of cotrimoxazole tablets in healthy Chinese subjects. All 26 subjects recruited to this study were randomly and evenly classified into two groups and received a single dose (sulfamethoxazole: 400 mg and trimethoprim: 80 mg) of test cotrimoxazole tablets (generic drug) or reference cotrimoxazole tablets (branded drug). After a 7-day washout period, these subjects received one dose of reference drug or test drug. Blood samples were collected from participants before and up to 48 h after dosing to assess the concentration of sulfamethoxazole (SMX) and trimethoprim (TMP) in plasma and a plasma concentration-time curve was drawn. Then, the pharmacokinetics parameters were calculated accordingly. Our data revealed that there were no significant differences observed in the maximum plasma concentration (Cmax), area under the curve from time 0 to the last measurable concentration (AUC0-t), and area under the curve from time 0 to infinity (AUC0-∞) between the two formulations. For SMX, the 90% confidence intervals (CI) of the geometric mean ratio for Cmax, AUC0-t, and AUC0-∞ were 104.03-113.92%, 100.46-103.70%, and 100.41-103.81%, respectively. Similarly, for Trimethoprim (TMP), the 90% CI ranged from 98.54 to 106.95% for Cmax, from 99.31 to 107.68% for AUC0-t, and from 99.49 to 107.55% for AUC0-∞. Importantly, all these 90% CI values fell within the range of 80.00–125.00%, indicating that the test drug is bioequivalent to the reference drug. Furthermore, throughout the entire trial, no suspected serious adverse events were reported, indicating the safety profile of the newly developed generic cotrimoxazole. In summary, our study demonstrates that the newly developed generic formulation of cotrimoxazole is bioequivalent to the branded formulation under fasting conditions.

Bioequivalence and pharmacokinetic study of trimetazidine dihydrochloride in human plasma by using LC-MS/MS

LC/ESI-MS Method for the Determination of Trimetazidine in Human Plasma: Application to a Bioequivalence Study on Chinese Volunteers.

Bioequivalence of trimetazidine dihydrochloride tablets in Chinese healthy subjects

[Pharmacokinetics and Bioequivalence of Domestic Trimetazidine Formulations].

Bioequivalence and Pharmacokinetic Profiles of 2 Trimetazidine Modified-release Tablets Under Fasting and Fed Conditions in Chinese Healthy Subjects

Study on bioequivalence of cilostazol table in healthy volunteers

Studies on the Bioequivalence of Lorazepam Tablet in Healthy Volunteers

Studies on Bioequivalence of Ramipril Capsule in Healthy Volunteers

Pharmacokinetics of Trimetazidines Tablets in Chinese Healthy Volunteers

Simultaneous determination of tramadol and its active metabolite 3-O-demethyltra-madol in human plasma by LC-MS/MS and its application to bioequivalence

Pharmacokinetics and bioequivalence evaluation of two oral formulations of cotrimoxazole tablets in healthy Chinese volunteers under fasting conditions

Evaluation of Bioequivalence of Mirtazapine Tablets

Determination of Amlodipine Concentration in Human Plasma by LC-MS/MS Method and Bioequivalence Study of Its Tablets

Determination of Telmisartan in Human Plasma by LC-MS/MS and Bioequivalence Study of It

An LC-MS/MS method for simultaneous determination of cefprozil diastereomers in human plasma and its application for the bioequivalence study of two cefprozil tablets in healthy Chinese volunteers.

Study on bioequivalence of tramadol chloride tablets

Determination by HPLC-MS-MS Method and Bioequivalence of Clemastine in Health Volunteers

Determination of Gliquidone in Human Plasma by LC-MS/MS and Bioequivalence Study of Its Two Tablets

Determination of Binding Rate of Trimetazidine and Human Plasma Protein

Study on Bioequivalence of Risperidone Tablets

Simultaneous Determination of Paracetamol and Amantadine in Human Plasma and Bioequivalence of Its Preparations in Healthy Volunteers by LC-MS